
10 High Cost Drugs Losing Patent Protection in 2016
Generic drugs are generally lower cost for insurers than brand name drugs. Here are 10 drugs coming off patent in 2016. Although the FDA has not yet approved generics for these drugs they are in the pipeline. The drugs are listed below: 1. Humira - used for: Rheumatoid arthritis Manufactured by: Abbvie Estimated annual sales: $12.54 billion Generic approved: Biosimilars in the pipeline, no generic approved 2. Crestor - used for: Lower bad cholesterol (LDL), raise good